Insulet Corporation (PODD)
Insulet (PODD) Q3 Earnings and Revenues Top Estimates
Insulet (PODD) came out with quarterly earnings of $0.90 per share, beating the Zacks Consensus Estimate of $0.77 per share. This compares to earnings of $0.71 per share a year ago.
Insulet raises annual revenue forecast on strong demand for insulin pumps
Insulet raised its annual revenue growth forecast on Thursday, banking on strong demand for its wearable insulin pumps.
Insulet Stock Gains From Expansion Strategies, Innovation
PODD continues to drive increased awareness for Omnipod through its direct-to-consumer advertising campaign.
Stay Ahead of the Game With Insulet (PODD) Q3 Earnings: Wall Street's Insights on Key Metrics
Get a deeper insight into the potential performance of Insulet (PODD) for the quarter ended September 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Insulet (PODD) Earnings Expected to Grow: Should You Buy?
Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Insulet Stock a Smart Addition to Your Portfolio Right Now?
PODD continues to make strides with Omnipod 5 and its market expansion. Robust solvency is a plus.
Should You Continue to Retain PODD Stock in Your Portfolio Now?
Insulet's Omnipod 5 is set to drive growth in the upcoming quarters. Meanwhile, the stock is facing challenges due to economic uncertainties.
What Helped Insulet Stock Gain 10% This Week?
Insulet stock (NASDAQ: PODD) currently trades around $200 per share, about 35% lower than the levels of over $300 seen in early November 2021. In comparison, its peer – DexCom stock – is down 55% over this period.
Why Insulet Stock Was Zooming Higher This Week
The highly specialized medical device maker earns an important nod from a top regulator. A label expansion could potentially reach a market of 6 million people.
Insulet's Omnipod 5 Wins FDA Approval for Type 2 Diabetes
PODD marks a major milestone with Omnipod 5 approval for the treatment of type 2 diabetes.
This Healthcare Stock Is the Best Performer in the S&P 500 Tuesday
Insulet got a key FDA approval for an insulin delivery system.
These Two Stocks Plunged After Eli Lilly Drug Study Showed Diabetes Promise
Shares of Insulet (PODD) and DexCom (DXCM), two companies that provide medical devices for patients managing diabetes, tumbled Tuesday after a study showed that a popular drug made by Eli Lilly (LLY) significantly lowers the risk of developing type 2 diabetes.
